Yarrow Bioscience, Inc.

Healthcare · Biotechnology · United States

Last price 20 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 186.09M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company’s candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves’ disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.